Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: SARIFA as a new histopathological biomarker is associated with adverse clinicopathological characteristics, tumor-promoting fatty-acid metabolism, and might predict a metastatic pattern in pT3a prostate cancer

Fig. 4

Exemplary maximum intensity projections of PSMA-PET/CT at point of first biochemical recurrence. A SARIFA-negative pT3a prostate cancer patient with a PSMA-positive iliaco-internal lymph node (marked by white arrow). B SARIFA-positive pT3a prostate cancer patient with PSMA-positive regional as well as distant lymph node (marked by white arrow) involvement as well as several bone metastasis. Distant lymph nodes were defined as all extra-pelvic lymph node manifestations. pT: depth of invasion, PET/CT: Positron emission tomography/Computed tomography, PSMA: prostate-specific membrane antigen, SARIFA: Stroma-AReactive-Invasion-Front-Areas SUV: standardized uptake volume

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us